Pfizer Inc. (NYSE:PFE): Closing price $29.54
Pfizer will supply hundreds of millions of doses of its lucrative vaccine against pneumonia and meningitis at a large discount for young children living in poor countries. The arrangement to provide 260 million shots of its Prevnar 13 vaccine for a few dollars apiece is the drug maker’s third agreement through an innovative program by which pharmaceutical firms, governments, health groups, and charities work jointly to bring poorer countries a long-term supply of affordable vaccines against deadly diseases. Prevnar 13 protects against 13 strains of pneumococcal disease.
A court decision in the United States has derailed a plan by Teva to transition patients to a longer-acting version of its Copaxone treatment, as the ruling afforded the $4 billion drug less than a year of patent protection. The company wants to move up to half of the multiple-sclerosis patients taking daily Copaxone injections to a three-times-weekly version, but the U.S. Court of Appeals’ action to invalidate a 2015 patent may permit generic rivals like Momenta Pharmaceuticals Inc. to entice patients with less expensive copies as soon as 2014, UBS analyst Marc Goodman said.
Prana Biotechnology (NASDAQ:PRAN): Closing price $3.81
On Monday, Prana said that the initial patient has been dosed in the 12-month open-label extension study with Alzheimer’s Disease patients participating in Prana’s Phase 2 IMAGINE trial. Patients who have finished the full 12-month term of the IMAGINE trial may participate in the open-label Extension evaluation. All participants in the Extension study will receive a once daily oral 250mg dose of PBT2 for an additional 12 months. The trial is a 12-month double-blind Phase 2 clinical trial of PBT2 in mild or prodromal Alzheimer’s patients. The Extension study does not change the completion and reporting on the trial with results anticipated in March.
Novavax, Inc. (NASDAQ:NVAX): Closing price $2.51
Novavax announced on Monday positive preclinical data for its virus-like particle vaccine candidate against A(H7N9) influenza. The data were published online in the peer-reviewed journal Vaccine. The study explored the immunogenicity and efficacy of two doses of its A(H7N9) VLP vaccine candidate against a lethal wild-type challenge mouse model. Novavax’ non-homologous A(H7N3) VLP vaccine candidate was included in three control groups, its A(H5N1) VLP vaccine candidate, and a placebo. All vaccine candidates were administered with or without Iscomatrix, which is a saponin-based adjuvant.
Don’t Miss: FDA Is Restricting This Johnson & Johnson Drug.